Abstract
N-Ethyl-2-pyrrolidone (NEP) is an industrial solvent that has been increasingly used to substitute N-methyl-2-pyrrolidone. NEP is under scrutiny in scientific and regulatory committees because of developmental toxic and teratogenic effects in rodents. The two postulated NEP metabolites 5-hydroxy-N-ethyl-2-pyrrolidone (5-HNEP) and 2-hydroxy-N-ethylsuccinimide (2-HESI) have recently been detected in urine samples from the general population. Thus, the toxicokinetic characterization of these biomarkers of NEP exposure in humans is of relevance both in the occupational as well as the environmental field. We orally dosed 20.9 mg NEP to three male volunteers. These volunteers collected all their urine samples over a period of 4 days post dose. In these samples we identified and quantified the above postulated NEP metabolites 5-HNEP and 2-HESI and determined their urinary elimination kinetics and their metabolic conversion factors. After 4 days we recovered 50.7 % of the dose as these two metabolites in urine, 29.1 % as 5-HNEP and 21.6 % as 2-HESI. The largest share of 5-HNEP was excreted within 24 h post dose, while the major share of 2-HESI was excreted on day 2 post dose. We estimated an elimination half-time for 5-HNEP of approx. 7 h and for 2-HESI of approx. 22–27 h. While the elimination of 5-HNEP was basically finished 72 h post dose, significant amounts of 2-HESI were still eliminated after 96 h. Both biomarkers can now be used in human biomonitoring studies to extrapolate from urinary measurements to the NEP dose taken up and thus to evaluate the risk caused by exposure to this chemical.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Åkesson B, Jönsson BA (1997) Major metabolic pathway for N-methyl-2-pyrrolidone in humans. Drug Metab Dispos 25(2):267–269
Åkesson B, Jönsson BA (2000) Biological monitoring of N-methyl-2-pyrrolidone using 5-hydroxy-N-methyl-2-pyrrolidone in plasma and urine as the biomarker. Scand J Work Environ Health 26(3):213–218
Åkesson B, Carnerup M, Jönsson BA (2004) Evaluation of exposure biomarkers from percutaneous absporption of N-methyl-2-pyrrolidone. Scand J Work Environ Health 30(4):306–312
Anundi H, Lind ML, Friis L, Itkes N, Langworth S, Edling C (1993) High exposures to organic solvents among graffiti removers. Int Arch Occup Environ Health 65(4):247–251
Anundi H, Langworth S, Johanson G, Lind ML, Åkesson B, Friis L, Itkes N, Söder-man E, Jönsson BA, Edling C (2000) Air and biological monitoring of solvent exposure during graffiti removal. Int Arch Occup Environ Health 73(8):561–569
Bader M, Keener SA, Wrbitzky R (2005) Dermal absorption and urinary elimination of N-methyl-2-pyrrolidone. Int Arch Occup Environ Health 78(8):673–676
Bader M, Rosenberger W, Rebe Th, Keener SA, Brock TH, Hemmerling HJ, Wrbitzky R (2006) Ambient monitoring and biomonitoring of workers exposed to N-methyl-2-pyrrolidone in an industrial facility. Int Arch Occup Environ Health 79(5):357–364
Bader M, Wrbitzky R, Blaszkewicz M, van Thriel C (2007) Human experimental exposure study on the uptake and urinary elimination of N-methyl-2-pyrrolidone (NMP) during simulated workplace conditions. Arch Toxicol 81(5):335–346
Bader M, Wrbitzky R, Blaszkewicz M, Schäper M, vanThriel Ch (2008) Human volunteer study on the inhalational and dermal absorption of N-methyl-2-pyrrolidone (NMP) from the vapour phase. Arch Toxicol 82(1):13–20
Carnerup MA, Spanne M, Jönsson BA (2006) Levels of N-methyl-2-pyrrolidone (NMP) and its metabolites in plasma and urine from volunteers after experimental exposure to NMP in dry and humid air. Toxicol Lett 162(2–3):139–145
ECHA—European Chemicals Agency (2011) Committee for Risk Assessment (RAC), Annex 1, Background document to the Opinion proposing harmonised classification and labelling at Community level of N-ethyl-2-pyrrolidone (NEP), ECHA/RAC/CLH-O-0000002192-83-01/A1, adopted 29 Nov 2011
Gries W, Ellrich D, Küpper K, Ladermann B, Leng G (2012) Analytical method for the sensitive determination of major di-(2-propylheptyl)-phthalate metabolites in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 908:128–136
Jönsson BA, Akesson B (2003) Human experimental exposure to N-methyl-2-pyrrolidone (NMP): toxicokinetics of NMP, 5-hydroxy-N-methyl-2-pyrrolidone, N-methylsuccinimide and 2-hydroxy-N-methylsuccinimide (2-HMSI), and biological monitoring using 2-HMSI as a biomarker. Int Arch Occup Environ Health 76(4):267–274
Koch HM, Schütze A, Pälmke C, Angerer J, Brüning T (2013) Metabolism of the plasticizer and phthalate substitute diisononyl-cyclohexane-1,2-dicarboxylate (DINCH(®)) in humans after single oral doses. Arch Toxicol 87(5):799–806
Ligocka D, Lison D, Haufroid V (2003) Contribution of CYP2E1 to N-methyl-2-pyrrolidone metabolism. Arch Toxicol 77(5):261–266
Midgley I, Hood AJ, Chasseaud LF, Brindley CJ, Baughman S, Allan G (1992) Percutaneous absorption of co-administered N-methyl-2-[14C]pyrrolidinone and 2-[14C]pyrrolidinone in the rat. Food Chem Toxicol 30(1):57–64
Saillenfait AM, Gallissot F, Langonné I, Sabaté JP (2002) Developmental toxicity of N-methyl-2-pyrrolidone administered orally to rats. Food Chem Toxicol 40(11):1705–1712
Saillenfait AM, Gallissot F, Sabaté JP (2007) Developmental toxic effects of N-ethyl-2-pyrrolidone administered orally to rats. J Appl Toxicol 27(5):491–497
Schindler BK, Koslitz S, Meier S, Belov VN, Koch HM, Weiss T, Brüning T, Käfferlein HU (2012) Quantification of four major metabolites of embryotoxic N-methyl- and N-ethyl-2-pyrrolidone in human urine by cooled-injection gas chromatography and isotope dilution mass spectrometry. Anal Chem 84(8):3787–3794
Schütze A, Pälmke C, Angerer J, Weiss T, Brüning T, Koch HM (2012) Quantification of biomarkers of environmental exposure to di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH) in urine via HPLC–MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 895–896:123–130
Wells DA, Hawi AA, Digenis GA (1992) Isolation and identification of the major urinary metabolite of N-methylpyrrolidinone in the rat. Drug Metab Dispos 20(1):124–126
Xiaofei E, Wada Y, Nozaki JI, Miyauchi H, Tanaka S, Seki Y, Koizumi A (2000) A linear pharmakokinetic model predicts usefulness of N-methyl-2-pyrrolidone (NMP) in plasma or urine as a biomarker for biological monitoring for NMP exposure. J Occup Health 42:321–327
Acknowledgments
The study was carried out as part of a 10-year project to foster human biomonitoring in Germany. This project is a cooperation agreed upon in 2010 between the German Federal Ministry for the Environment, Nature Conservation and Nuclear Safety (BMU) and the Verband der Chemischen Industrie e.V. (German Chemical Industry Association—VCI) and is administered by the German Federal Environment Agency (UBA). The study aims on the development of a new method for the analysis of urinary NEP including the identification and validation of biomarkers of NEP exposure (by means of a human metabolism study) was funded by the German Chemical Industry Association (c/o Chemie Wirtschaftsförderungsgesellschaft mbH). Experts from government authorities, industry and science accompany substance selection, method development and application throughout the whole project.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koch, H.M., Bader, M., Weiss, T. et al. Metabolism and elimination of N-ethyl-2-pyrrolidone (NEP) in human males after oral dosage. Arch Toxicol 88, 893–899 (2014). https://doi.org/10.1007/s00204-013-1150-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-013-1150-1